Applications & protocols
Where this is used, and on what basis.
Regenerative Powder · clinical integration
Three integration points
- 01
With microneedling
Fractional RF or standard pen devices
Applied topically immediately after, or during, the microneedling pass.
Rationale
Micro-channels give direct access to the dermal compartment for the duration of the treatment window, so the preparation reaches the tissue where the matrix response is being initiated.
- 02
After energy-based devices
CO₂, erbium, thulium, RF
Applied immediately following ablative or non-ablative treatment.
Rationale
Energy-based procedures generate thermal and oxidative stress alongside the intended remodeling stimulus. Application in the immediate post-procedure window targets the recovery phase rather than the injury itself.
- 03
Standalone delivery
Mesotherapy, electroporation, sonophoresis
Delivered through transdermal systems as a needle-free treatment.
Rationale
For patients or indications where a procedural stimulus is not wanted, transdermal delivery targets the same layers without the downtime that comes with a device pass.
Scope of these protocols
These describe how the preparation is integrated into clinician-directed procedures within its authorized topical cosmetic use. They are not treatment claims, and outcomes are not guaranteed. All use follows local regulatory requirements and clinician judgement.
Biological rationale
What the composition is expected to contribute
- Matrix scaffolding
- Fibronectin and the wider ECM protein fraction contribute to the adhesion and migration context fibroblasts work within.
- Redox buffering
- The redox and oxidative-stress enzyme fraction is relevant to the post-procedure window, where oxidative load is elevated.
- Remodeling balance
- MMP and TIMP systems regulate the balance between matrix breakdown and rebuilding. Repair needs both, in sequence.
Functional potency assays give the evidence for these rationales. See the assay data.
PEXT CM · development directions
Ten directions under development
How to read this list
These are development and research directions, not approved treatment claims. PEXT CM is not positioned as a cancer treatment, a cancer-prevention product, or a substitute for oncologic care. Its post-oncology concept concerns recovery biology after the primary treatment pathway has been completed or clinically stabilized, under clinician evaluation.
- 01
Post-oncology tissue recovery
Supportive recovery biology after chemotherapy, radiotherapy and oncologic procedures.
- 02
Radiation-related skin recovery
Supporting the tissue microenvironment affected by radiotherapy-related skin stress.
- 03
Oral and mucosal barrier recovery
A potential topical or mucosal platform for treatment-related barrier injury.
- 04
Chronic and difficult-to-heal wounds
A whole-secretome approach to chronic wound microenvironment support.
- 05
Diabetic foot and trophic ulcers
Potential adjunctive support where chronic inflammation and oxidative stress impair repair.
- 06
Surgical and post-procedural recovery
Supporting dermal matrix remodeling and barrier repair after invasive or energy-based procedures.
- 07
Scar quality and matrix remodeling
Pathways involved in collagen organization, ECM remodeling and tissue architecture.
- 08
Advanced dermatologic recovery
After laser, microneedling, RF, peeling and other aesthetic or dermatologic procedures.
- 09
Skin quality and regenerative dermatology
Dermal matrix biology, redox resilience and regenerative skin microenvironment signalling.
- 10
Recovery biology and functional resilience
An investigational direction for post-treatment oxidative-stress burden and recovery-phase resilience.
Post-oncology recovery
Supporting the biology of recovery after intensive treatment
Cancer treatment places a major biological burden on tissue. Chemotherapy, radiotherapy, immunotherapy and surgery may affect mucosal barriers, skin integrity, wound healing, redox balance, inflammatory tone and functional recovery.
PEXT CM is being developed around post-treatment recovery biology: supporting the regenerative microenvironment after the primary oncologic pathway has been completed or clinically stabilized.
The goal is not to target cancer. The goal is to support the patient’s recovery biology after treatment-related tissue stress.
Suggested clinical research direction
- Post-radiotherapy skin and soft tissue recovery
- Treatment-related mucosal barrier stress
- Surgical wound recovery after oncologic procedures
- Recovery-phase fatigue and biological resilience research
- Oxidative-stress and inflammation-related recovery monitoring
For clinicians
For professionals seeking a characterized cell-free platform
PEXT is intended for clinician-directed, evidence-aware regenerative applications where the goal is to support the tissue microenvironment rather than deliver live cells.
Clinician interest areas
- Regenerative dermatology
- Post-procedure recovery
- Chronic wound support
- Post-radiotherapy skin recovery
- Mucosal barrier recovery
- Scar quality and matrix remodeling
- Recovery biology after intensive treatment